Milap Shah1,2, Nithesh Naik2,3, Bhaskar K Somani2,4, B M Zeeshan Hameed1,2,5. 1. Department of Urology, Kasturba Medical College Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India. 2. i-TRUE: International Training and Research in Uro-oncology and Endourology, Manipal, Karnataka, India. 3. Department of Mechanical and Manufacturing Engineering, Manipal Institute of Technology, Manipal Academy of Higher Education, Manipal, Karnataka, India. 4. Department of Urological Surgery, University Hospital Southampton NHS Trust, Southampton, UK. 5. KMC Innovation Centre, Manipal Academy of Higher Education, Manipal, Karnataka, India.
Abstract
OBJECTIVE: Artificial intelligence (AI) is used in various urological conditions such as urolithiasis, pediatric urology, urogynecology, benign prostate hyperplasia (BPH), renal transplant, and uro-oncology. The various models of AI and its application in urology subspecialties are reviewed and discussed. MATERIAL AND METHODS: Search strategy was adapted to identify and review the literature pertaining to the application of AI in urology using the keywords "urology," "artificial intelligence," "machine learning," "deep learning," "artificial neural networks," "computer vision," and "natural language processing" were included and categorized. Review articles, editorial comments, and non-urologic studies were excluded. RESULTS: The article reviewed 47 articles that reported characteristics and implementation of AI in urological cancer. In all cases with benign conditions, artificial intelligence was used to predict outcomes of the surgical procedure. In urolithiasis, it was used to predict stone composition, whereas in pediatric urology and BPH, it was applied to predict the severity of condition. In cases with malignant conditions, it was applied to predict the treatment response, survival, prognosis, and recurrence on the basis of the genomic and biomarker studies. These results were also found to be statistically better than routine approaches. Application of radiomics in classification and nuclear grading of renal masses, cystoscopic diagnosis of bladder cancers, predicting Gleason score, and magnetic resonance imaging with computer-assisted diagnosis for prostate cancers are few applications of AI that have been studied extensively. CONCLUSIONS: In the near future, we will see a shift in the clinical paradigm as AI applications will find their place in the guidelines and revolutionize the decision-making process.
OBJECTIVE: Artificial intelligence (AI) is used in various urological conditions such as urolithiasis, pediatric urology, urogynecology, benign prostate hyperplasia (BPH), renal transplant, and uro-oncology. The various models of AI and its application in urology subspecialties are reviewed and discussed. MATERIAL AND METHODS: Search strategy was adapted to identify and review the literature pertaining to the application of AI in urology using the keywords "urology," "artificial intelligence," "machine learning," "deep learning," "artificial neural networks," "computer vision," and "natural language processing" were included and categorized. Review articles, editorial comments, and non-urologic studies were excluded. RESULTS: The article reviewed 47 articles that reported characteristics and implementation of AI in urological cancer. In all cases with benign conditions, artificial intelligence was used to predict outcomes of the surgical procedure. In urolithiasis, it was used to predict stone composition, whereas in pediatric urology and BPH, it was applied to predict the severity of condition. In cases with malignant conditions, it was applied to predict the treatment response, survival, prognosis, and recurrence on the basis of the genomic and biomarker studies. These results were also found to be statistically better than routine approaches. Application of radiomics in classification and nuclear grading of renal masses, cystoscopic diagnosis of bladder cancers, predicting Gleason score, and magnetic resonance imaging with computer-assisted diagnosis for prostate cancers are few applications of AI that have been studied extensively. CONCLUSIONS: In the near future, we will see a shift in the clinical paradigm as AI applications will find their place in the guidelines and revolutionize the decision-making process.
Authors: Peter Ström; Kimmo Kartasalo; Henrik Olsson; Leslie Solorzano; Brett Delahunt; Daniel M Berney; David G Bostwick; Andrew J Evans; David J Grignon; Peter A Humphrey; Kenneth A Iczkowski; James G Kench; Glen Kristiansen; Theodorus H van der Kwast; Katia R M Leite; Jesse K McKenney; Jon Oxley; Chin-Chen Pan; Hemamali Samaratunga; John R Srigley; Hiroyuki Takahashi; Toyonori Tsuzuki; Murali Varma; Ming Zhou; Johan Lindberg; Cecilia Lindskog; Pekka Ruusuvuori; Carolina Wählby; Henrik Grönberg; Mattias Rantalainen; Lars Egevad; Martin Eklund Journal: Lancet Oncol Date: 2020-01-08 Impact factor: 41.316
Authors: Heidi Coy; Kevin Hsieh; Willie Wu; Mahesh B Nagarajan; Jonathan R Young; Michael L Douek; Matthew S Brown; Fabien Scalzo; Steven S Raman Journal: Abdom Radiol (NY) Date: 2019-06
Authors: D J Bägli; S K Agarwal; S Venkateswaran; B Shuckett; A E Khoury; P A Merguerian; G A McLorie; K Liu; C S Niederberger Journal: J Urol Date: 1998-09 Impact factor: 7.450
Authors: Bettina Baessler; Tim Nestler; Daniel Pinto Dos Santos; Pia Paffenholz; Vikram Zeuch; David Pfister; David Maintz; Axel Heidenreich Journal: Eur Radiol Date: 2019-12-11 Impact factor: 5.315
Authors: Satish E Viswanath; Prathyush V Chirra; Michael C Yim; Neil M Rofsky; Andrei S Purysko; Mark A Rosen; B Nicolas Bloch; Anant Madabhushi Journal: BMC Med Imaging Date: 2019-02-28 Impact factor: 1.930
Authors: Sudeh Izadmehr; Dara J Lundon; Nihal Mohamed; Andrew Katims; Vaibhav Patel; Benjamin Eilender; Reza Mehrazin; Ketan K Badani; John P Sfakianos; Che-Kai Tsao; Peter Wiklund; William K Oh; Carlos Cordon-Cardo; Ashutosh K Tewari; Matthew D Galsky; Natasha Kyprianou Journal: Front Oncol Date: 2021-09-27 Impact factor: 6.244